Ro balancing D2C speed and enterprise rigor

Ro’s real challenge is changing from a fast checkout funnel into a health benefit vendor without breaking the simple consumer experience that made it work. D2C speed came from free consults, cash pay, contractor clinicians, and subscription drug fulfillment. Selling to employers and payers adds account management, outcomes reporting, coverage workflows, and tighter clinical process, especially in GLP-1 care where labs, titration, side effect monitoring, and adherence support matter every month.1 2 3

• Ro already built more operational depth than a typical telehealth storefront. It tied together home testing, in home phlebotomy, owned labs, and owned pharmacies so a patient can do intake, get labs, adjust dose, and receive medication inside one flow. That stack helps with employer grade control, but it is heavier to run than the old ED subscription model.1 2
• The buyer and proof points change in employer and payer sales. Consumer users buy on convenience and brand. HR and health plans buy on whether the program lowers spend and keeps patients adherent. Virta sells with outcomes tied to fees and high retention, while Maven wins with reporting, broad provider networks, and benefit administration across large workforces.2 3 4
• Ro’s growth engine is still strongest in consumer channels. Revenue accelerated from an estimated $360M in 2023 to $598M in 2024 as GLP-1 demand surged, but cash pay channels are getting more commoditized as manufacturer direct pharmacy options expand. That makes enterprise distribution more important, even though incumbents there start with embedded relationships and procurement muscle.2 5

The next phase of telehealth belongs to companies that can hide enterprise complexity behind a clean patient experience. If Ro can keep the front end feeling like a simple app while building the back end discipline of a benefits platform, it can move from being a marketer of care episodes to a long term obesity and chronic care partner.2 3 4